**Table S2: Continuous monitoring for severe toxicity by Pocock-type boundary\***

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of Patients, *n* | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| Boundary, *bn* | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Number of Patients, *n* | 21 | 22 | 23 | 24 | 25 |  |
| Boundary, *bn* | 4 | 4 | 4 | 4 | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

 \* The trial will be stopped if the number of patients died in remission is equal to or exceeds bn out of n patients with completed follow-up.